Natriuretic peptides as prognostic and diagnostic markers in Chagas' disease

Puyó, Ana María; Scaglione, Jorge; Auger, Sergio; Cavallero, Susana; Postan, Miriam; Fernández, Belisario E.

doi:10.1016/j.regpep.2005.01.001

Cited by 10 publications

(8 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these, 579 were excluded because they did not meet inclusion criteria by a reading of titles and abstracts. Seventeen more articles 4 -20 were excluded after reading the entire article: 15 4,5,[7][8][9][10][11][12][13][15][16][17][18][19][20] because of ineligibility, and 2 6,14 because they were written on the same or overlapping data sets of a subsequent 21 or previous 22 report. Two articles from an external source were added to this overview: a manuscript that had just been accepted for publication in a peer-reviewed journal 23 and a relevant study (published as an abstract) 24 that was identified by searching for bibliographies in all retrieved articles.…”

Section: Resultsmentioning

confidence: 99%

Predictors of Mortality in Chronic Chagas Disease

Rassi¹,

Rassi²

2007

Circulation

279

131

View full text Add to dashboard Cite

Background-Chagas disease is a major cause of morbidity and mortality in Latin America. Knowledge of the predictors of prognosis can help clinical decision making by identifying patients' level of risk. Methods and Results-We reviewed the published literature on prognostic factors in patients with Chagas disease by performing a PubMed search for articles published in any language between 1985 and February 2006 and hand searches of the reference lists of retrieved articles. Studies were selected if they included patients in the chronic phase of Chagas disease, analyzed a clearly defined outcome (all-cause mortality, sudden cardiac deaths, and/or cardiovascular deaths), and used multivariable regression models of prognosis. From 606 potentially relevant studies, 12 met the inclusion criteria: 8 clinic-based studies including 3928 patients and 4 hospital-based studies including 349 patients. Impaired left ventricular function by echocardiogram or cineventriculogram was found to be the most common and consistent independent predictor of death. New York Heart Association functional class III/IV and cardiomegaly on the chest radiography also were independently associated with higher mortality. More recently, strong evidence was found that nonsustained ventricular tachycardia on 24-hour Holter monitoring indicated an adverse prognosis. The typical ECG abnormalities showed limited additional prognostic value. Other often-mentioned risk factors, advanced age and male sex, showed inconsistent results. A formal meta-analysis was not feasible because of the heterogeneity of published studies and the lack of minimal standards in reporting results. Conclusions-A systematic review of published studies indicates that impaired left ventricular function, New York HeartAssociation class III/IV, cardiomegaly, and nonsustained ventricular tachycardia indicate a poor prognosis in patients with chronic Chagas disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Predictors of Mortality in Chronic Chagas Disease

Rassi¹,

Rassi²

2007

Circulation

279

131

View full text Add to dashboard Cite

show abstract

“…Specific cardiological markers, such as troponin I and T and natriuretic peptides [i.e., atrial natriuretic peptide, brain natriuretic peptide (BNP) and N-terminal proBNP], have been proposed to determine disease progression when myocardial involvement was assessed both in the early ( Puyó et al 2002 , 2005 , Ribeiro et al 2003 , Heringer-Walther et al 2005 , Moreira et al 2008 , García-Alvarez et al 2010 , Lima-Costa et al 2010 ) and late ( Puyó et al 2002 , Heringer-Walther et al 2005 , Machado et al 2005 ) stages of the disease.…”

Section: Host Response/damage Biomarkersmentioning

confidence: 99%

Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives

Pinazo

Thomas²,

Bustamante

et al. 2015

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

The definition of a biomarker provided by the World Health Organization is any substance, structure, or process that can be measured in the body, or its products and influence, or predict the incidence or outcome of disease. Currently, the lack of prognosis and progression markers for chronic Chagas disease has posed limitations for testing new drugs to treat this neglected disease. Several molecules and techniques to detect biomarkers in Trypanosoma cruzi-infected patients have been proposed to assess whether specific treatment with benznidazole or nifurtimox is effective. Isolated proteins or protein groups from different T. cruzi stages and parasite-derived glycoproteins and synthetic neoglycoconjugates have been demonstrated to be useful for this purpose, as have nucleic acid amplification techniques. The amplification of T. cruzi DNA using the real-time polymerase chain reaction method is the leading test for assessing responses to treatment in a short period of time. Biochemical biomarkers have been tested early after specific treatment. Cytokines and surface markers represent promising molecules for the characterisation of host cellular responses, but need to be further assessed.

show abstract

“…In a longitudinal case-control follow-up study carried out in endemic areas over a period of 10 years, more than one-third of patients with chronic Chagas' disease experienced clinical or electrocardiographic deterioration [45]. Recently, atrial natriuretic factor has been shown as a sensitive marker capable of detecting gradual impairments in cardiac function and poor survival in Chagasic cardiomyopathy patients [46]. In symptomatic patients with chronic Chagas' heart disease, left ventricular dysfunction, old age, male gender, abnormal electrocardiogram, and elevated natriuretic peptides are adverse prognostic factors [32,[46][47][48].…”

Section: Prognosismentioning

confidence: 99%